HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SPG21
SPG21 abhydrolase domain containing, maspardin
Chromosome 15 Β· 15q22.31
NCBI Gene: 51324Ensembl: ENSG00000090487.12HGNC: HGNC:20373UniProt: Q9NZD8
49PubMed Papers
21Diseases
0Drugs
13Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingCD4 receptor bindingcytosoltrans-Golgi network transport vesiclemast syndromehereditary sensory and autonomic neuropathy with spastic paraplegiahereditary spastic paraplegiahereditary spastic paraplegia 5A
✦AI Summary

SPG21 encodes maspardin, a cytosolic protein that functions as a RAB7A effector involved in endolysosomal trafficking and signaling. The protein localizes to endolysosomes through interaction with GTP-bound RAB7A and controls the subcellular positioning of this GTPase 1. SPG21 regulates mTORC1-mediated phosphorylation of the transcription factor TFEB, promoting its cytoplasmic retention and suppressing nuclear translocation 12. Loss of SPG21 function disrupts RAB7 localization from retromer-positive late endosomes to lysosomes, leading to enhanced lysosomal motility and altered TFEB signaling 2. The protein also interacts with aldehyde dehydrogenase ALDH16A1 and localizes to trans-Golgi network/late endosomal compartments 3. Mutations in SPG21 cause autosomal recessive spastic paraplegia type 21 (Mast syndrome), characterized by spastic paraparesis, dementia, thin corpus callosum, and white matter abnormalities 34. Disease-associated variants reduce SPG21 expression and disrupt endolysosomal localization in neurons, linking dysfunction to altered endolysosomal signaling pathways 1. Beyond neurological disease, SPG21 has been implicated in hepatocellular carcinoma progression and chemoresistance through TRPM7/JNK pathway activation 5.

Sources cited
1
SPG21 functions as RAB7A effector, localizes to endolysosomes, regulates mTORC1-TFEB signaling, and disease variants disrupt localization
PMID: 40833810
2
SPG21 controls RAB7 positioning and lysosomal motility, affecting TFEB phosphorylation and nuclear translocation
PMID: 41400694
3
SPG21/maspardin interacts with ALDH16A1, localizes to cytoplasm and trans-Golgi network/late endosomes, and mutations cause Mast syndrome
PMID: 19184135
4
SPG21 mutations cause autosomal recessive spastic paraplegia with characteristic clinical features
PMID: 22554690
5
SPG21 is implicated in hepatocellular carcinoma progression through TRPM7/JNK pathway activation
PMID: 38753154
Disease Associationsβ“˜21
mast syndromeOpen Targets
0.75Strong
hereditary sensory and autonomic neuropathy with spastic paraplegiaOpen Targets
0.50Moderate
hereditary spastic paraplegiaOpen Targets
0.49Moderate
hereditary spastic paraplegia 5AOpen Targets
0.37Weak
alcohol drinkingOpen Targets
0.19Weak
SplenomegalyOpen Targets
0.19Weak
hepatocellular carcinomaOpen Targets
0.03Suggestive
Alzheimer diseaseOpen Targets
0.03Suggestive
neoplasmOpen Targets
0.01Suggestive
chronic rhinosinusitis with nasal polypsOpen Targets
0.01Suggestive
breast cancerOpen Targets
0.01Suggestive
bacterial diseaseOpen Targets
0.01Suggestive
hyperinsulinemic hypoglycemia, familial, 4Open Targets
0.01Suggestive
atopic eczemaOpen Targets
0.01Suggestive
allergic rhinitisOpen Targets
0.01Suggestive
dementiaOpen Targets
0.01Suggestive
HelminthiasisOpen Targets
0.01Suggestive
tarsal-carpal coalition syndromeOpen Targets
0.01Suggestive
asthmaOpen Targets
0.01Suggestive
multiple myelomaOpen Targets
0.01Suggestive
Spastic paraplegia 21, autosomal recessiveUniProt
Pathogenic Variants13
NM_016630.7(SPG21):c.118C>T (p.Arg40Ter)Pathogenic
Mast syndrome|not provided|Hereditary spastic paraplegia
β˜…β˜…β˜†β˜†2026β†’ Residue 40
NM_016630.7(SPG21):c.452+2T>CLikely pathogenic
Mast syndrome|Hereditary spastic paraplegia|not provided|SPG21-related disorder|Acute myeloid leukemia
β˜…β˜…β˜†β˜†2025
NM_016630.7(SPG21):c.601dup (p.Thr201fs)Pathogenic
Mast syndrome|Hereditary spastic paraplegia|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 201
NM_016630.7(SPG21):c.119dup (p.Ser41fs)Pathogenic
Mast syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 41
NM_016630.7(SPG21):c.736C>T (p.Arg246Ter)Pathogenic
not provided|Mast syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 246
NM_016630.7(SPG21):c.226-1G>ALikely pathogenic
Mast syndrome
β˜…β˜†β˜†β˜†2023
NM_016630.7(SPG21):c.137_138del (p.Leu46fs)Pathogenic
Mast syndrome
β˜…β˜†β˜†β˜†2023β†’ Residue 46
NM_016630.7(SPG21):c.153del (p.Val52fs)Likely pathogenic
Mast syndrome
β˜…β˜†β˜†β˜†2021β†’ Residue 52
NM_016630.7(SPG21):c.613C>T (p.Gln205Ter)Likely pathogenic
Hereditary spastic paraplegia
β˜…β˜†β˜†β˜†2020β†’ Residue 205
NM_016630.7(SPG21):c.345_346del (p.Gln116fs)Pathogenic
Mast syndrome
β˜…β˜†β˜†β˜†β†’ Residue 116
NM_016630.7(SPG21):c.487del (p.Lys162_Ile163insTer)Pathogenic
Mast syndrome
β˜†β˜†β˜†β˜†2023β†’ Residue 162
NM_016630.7(SPG21):c.118del (p.Arg40fs)Pathogenic
Mast syndrome
β˜†β˜†β˜†β˜†2023β†’ Residue 40
NM_016630.7(SPG21):c.322G>C (p.Ala108Pro)Pathogenic
Mast syndrome
β˜†β˜†β˜†β˜†2014β†’ Residue 108
View on ClinVar β†—
Related Genes
ALDH16A1Protein interaction95%SPG11Protein interaction95%SPG7Protein interaction91%SPARTProtein interaction88%AP5Z1Protein interaction87%PNPLA6Protein interaction86%
Tissue Expression6 tissues
Liver
100%
Brain
93%
Lung
91%
Heart
77%
Ovary
71%
Bone Marrow
60%
Gene Interaction Network
Click a node to explore
SPG21ALDH16A1SPG11SPG7SPARTAP5Z1PNPLA6
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q9NZD8
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.89LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.60 [0.41–0.89]
RankingsWhere SPG21 stands among ~20K protein-coding genes
  • #9,020of 20,598
    Most Researched49
  • #2,617of 5,498
    Most Pathogenic Variants13
  • #7,993of 17,882
    Most Constrained (LOEUF)0.89
Genes detectedSPG21
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
The hereditary spastic paraplegia type 21 (SPG21) protein is a RAB7A effector that promotes noncanonical mTORC1-catalyzed TFEB phosphorylation and cytoplasmic retention.
PMID: 40833810
Mol Biol Cell Β· 2025
1.00
2
Maspardin/SPG21 controls lysosome motility and TFEB phosphorylation through RAB7 positioning.
PMID: 41400694
J Cell Biol Β· 2026
0.90
3
ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease.
PMID: 26556829
Brain Β· 2016
0.80
4
[Effect of hepatitis B virus X gene on the expression of spastic paraplegia 21].
PMID: 21205478
Zhonghua Gan Zang Bing Za Zhi Β· 2010
0.70
5
Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1.
PMID: 19184135
Neurogenetics Β· 2009
0.60